Cerebrolysin and rehabilitation after stroke: the CARS study
Level of evidence: Human randomized study; clinical formulation
Research question
Which functional outcomes were measured when a clinical Cerebrolysin formulation was added to early post-stroke rehabilitation?
Study design
The multicenter study was randomized, double-blind, and placebo-controlled. Both groups received rehabilitation; the additional study intervention differed.
What was found?
The authors reported favorable outcomes for functional recovery and global assessment in the rehabilitation population studied.
Limitations and interpretation
A single trial is not a complete body of evidence. Results apply to the patient population, support, and clinical formulation studied. Cerebrolysin is a mixture; the results cannot be attributed to a RUO product with the same name without analytical substantiation.
Original publication
Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. PMID: 26564102. View the original publication on PubMed.
This summary is based on the available source description and abstract; it is not a complete systematic review.
All Peptidera products are intended solely for scientific research and laboratory use. Not for human or animal consumption, self-administration, diagnosis, or treatment.
Related research products
View product specifications and available batch documentation. The studies discussed were not conducted with Peptidera products and do not establish the efficacy of our products. For laboratory research only; not for human or animal consumption.